Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kidera, Yasuhiro ^a,b   Kawakami, Hisato ^b   Sakiyama, Tsutomu ^b   Okamoto, Kunio ^b   Tanaka, Kaoru ^b   Takeda, Masayuki ^b   Kaneda, Hiroyasu ^b   Nishina, Shin Ichi ^b   Tsurutani, Junji ^b   Fujiwara, Kimiko ^b   Nomura, Morihiro ^b   Yamazoe, Yuzuru ^b   Chiba, Yasutaka ^b   Nishida, Shozo ^a   Tamura, Takao ^b   Nakagawa, Kazuhiko ^b  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; MAGNESIUM; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG USE; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; LUNG CANCER; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; RENAL PROTECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STOMACH CANCER; VERY ELDERLY; BLOOD; CHEMICALLY INDUCED; DIET SUPPLEMENTATION; KIDNEY DISEASES; MULTIVARIATE ANALYSIS; NEOPLASMS; NUCLEOTIDE SEQUENCE; RISK;

CISPLATIN; CREATININE; DIETARY SUPPLEMENTS; DNA MUTATIONAL ANALYSIS; HUMANS; KIDNEY DISEASES; MAGNESIUM; MULTIVARIATE ANALYSIS; NEOPLASMS; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84904248691     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101902     Document Type: Article

References (32)

1. Rozencweig M, von Hoff DD, Slavik M, Muggia FM (1977) Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med 86: 803-812.
2. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320. (Pubitemid 41130944)
3. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007. (Pubitemid 351543900)
4. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23: 460-464. (Pubitemid 37176691)
5. dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC (2012) Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 86: 1233-1250.
6. Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25: 47-58. (Pubitemid 29178536)
7. Netten PM, de Mulder PH, Theeuwes AG, Willems JL, Kohler BE, et al. (1990) Intravenous magnesium supplementation during cisdiammine-dichloroplatinum administration prevents hypomagnesemia. Ann Oncol 1: 369-372. (Pubitemid 20320490)
8. Martin M, Diaz-Rubio E, Casado A, Lopez Vega JM, Sastre J, et al. (1992) Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol 15: 348-351.
9. Evans TR, Harper CL, Beveridge IG, Wastnage R, Mansi JL (1995) A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 31A: 174-178.
10. Vokes EE, Mick R, Vogelzang NJ, Geiser R, Douglas F (1990) A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia. Br J Cancer 62: 1015-1017.
11. Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcislo K, et al. (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44: 2608-2614.
12. Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54: 19-23. (Pubitemid 16093180)
13. National Comprehensive Cancer Network (2013) NCCN chemotherapy order templates. Available: http://www.nccn.org/ordertemplates. Accessed: 2013 Nov 11.
14. Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, et al. (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40: 293-308. (Pubitemid 27276133)
15. Hesketh PJ, Chansky K, Lau DH, Doroshow JH, Moinpour CM, et al. (2006) Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol 1: 537-544. (Pubitemid 47181401)
16. Ries F, Klastersky J (1986) Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8: 368-379. (Pubitemid 17235084)
17. Kovach JS, Moertel CG, Schutt AJ, Reitemeier RG, Hahn RG (1973) Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep 57: 357-359.
18. de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, et al. (2003) Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88: 1199-1206. (Pubitemid 36606333)
19. Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, et al. (1985) Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 28: 914-921. (Pubitemid 16148393)
20. Stewart AF, Keating T, Schwartz PE (1985) Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstetr Gynecol 153: 660-665. (Pubitemid 16205445)
21. Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A (1997) Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28: 35-40. (Pubitemid 27023774)
22. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, et al. (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44: 164-172.
23. Lajer H, Kristensen M, Hansen HH, Nielsen S, Frokiaer J, et al. (2005) Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 56: 535-542. (Pubitemid 41549156)
24. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, et al. (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167: 1477-1484. (Pubitemid 41713303)
25. Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, et al. (2009) Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 13: 578-584.
26. Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, et al. (2007) Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 93: 138-144. (Pubitemid 46866703)
27. Al Bahrani BJ, Moylan EJ, Forouzesh B, Della-Fiorentina SA, Goldrick AJ (2009) A short outpatient hydration schedule for cisplatin administration. Gulf J Oncol 5: 30-36.
28. Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, et al. (2001) Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92: 2639-2647. (Pubitemid 33049448)
29. Gridelli C, Maione P, Rossi A, Guerriero C, Ferrara C, et al. (2006) Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 17 (suppl 5): v72-v78. (Pubitemid 43985210)
30. Whelton A, Maurath CJ, Verburg KM, Geis GS (2000) Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 7: 159-175.
31. Pope JE, Anderson JJ, Felson DT (1993) A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153: 477-484. (Pubitemid 23064991)
32. Ripamonti CI, Bandieri E, Roila F (2011) Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 22 (suppl 6): vi69-vi77.